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ABSTRACT
Background The rarity of mutations in PALB2, CHEK2 and ATM
make it difﬁcult to estimate precisely associated cancer risks.
Population-based family studies have provided evidence that at least
some of these mutations are associated with breast cancer risk as high
as those associated with rare BRCA2 mutations. We aimed to estimate
the relative risks associated with speciﬁc rare variants in PALB2,
CHEK2 and ATM via a multicentre case-control study.
Methods We genotyped 10 rare mutations using the custom iCOGS
array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2
c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and
c.1343T>G and ATM c.7271T>G. We assessed associations with
breast cancer risk (42 671 cases and 42 164 controls), as well as
prostate (22 301 cases and 22 320 controls) and ovarian (14 542
cases and 23 491 controls) cancer risk, for each variant.
Results For European women, strong evidence of association with
breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95%
CI 1.39 to 8.52, p=7.1×10−5), PALB2 c.3113G>A OR 4.21 (95% CI
1.84 to 9.60, p=6.9×10−8) and ATM c.7271T>G OR 11.0 (95% CI
1.42 to 85.7, p=0.0012). We also found evidence of association with
breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26
(95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5)
and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence
for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03
(95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2
c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European
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men. No evidence of association with ovarian cancer was found for
any of these variants.
Conclusions This report adds to accumulating evidence that at least
some variants in these genes are associated with an increased risk of
breast cancer that is clinically important.
INTRODUCTION
The rapid introduction of massive parallel sequencing (MPS)
into clinical genetics services is enabling the screening of mul-
tiple breast cancer susceptibility genes in one assay at reduced
cost for women who are at increased risk of breast (and other)
cancer. These gene panels now typically include the so-called
‘moderate-risk’ breast cancer susceptibility genes, including
PALB2, CHEK2 and ATM.1–3 However, mutations in these
genes are individually extremely rare and limited data are avail-
able with which to accurately estimate the risk of cancer asso-
ciated with them.
Estimation of the age-speciﬁc cumulative risk (penetrance) of
breast cancer associated with speciﬁc mutations in these three
genes has been limited to those that have been observed more
frequently, such as PALB2 c.1592delT (a Finnish founder muta-
tion), PALB2 c.3113G>A and ATM c.7271T>G. These muta-
tions have been estimated to be associated with a 40% (95% CI
17% to 77%), 91% (95% CI 44% to 100%) and 52% (95% CI
28% to 80%) cumulative risk of breast cancer to the age of
70 years, respectively.4–7 These ﬁndings, based on segregation
analyses in families of population-based case series, indicate that
at least some mutations in these ‘moderate-risk’ genes are asso-
ciated with a breast cancer risk comparable to that of the
average pathogenic mutation in BRCA2: 45% (95% CI 31% to
56%).8 However, such estimates are imprecise and, moreover,
may be confounded by modifying genetic variants or other
familial risk factors.
Case-control studies provide an alternative approach to
estimating cancer risks associated with speciﬁc variants. This
design can estimate the relative risk directly, without making
assumptions about the modifying effects of other risk factors.
However, because these variants are rare, such studies need to
be extremely large to provide precise estimates.
The clearest evidence for association, and the most precise
breast cancer risk estimates, for rare variants in PALB2, CHEK2
and ATM relate to protein truncating and splice-junction var-
iants.9 10 However, studies based on mutation screening in case-
control studies, combined with stratiﬁcation of variants by their
evolutionary likelihood suggest that at least some evolutionarily
unlikely missense substitutions are associated with a similar risk
to those conferred by truncating mutations.11–13 For example,
Tavtigian et al12 estimated an OR of 2.85 (95% CI 0.83 to
4.86) for evolutionarily unlikely missense substitutions in the 30
third of ATM, which is comparable to that for truncating var-
iants. Speciﬁcally, ATM c.7271C>G has been associated with a
more substantial breast cancer risk in several studies.7 13 Le
Calvez-Kelm et al,11 estimated that the ORs associated with rare
mutations in CHEK2 from similarly designed studies were 6.18
(95% CI 1.76 to 21.8) for rare protein-truncating and splice-
junction variants and 8.75 (95% CI 1.06 to 72.2) for evolution-
arily unlikely missense substitutions.11
It is plausible that monoallelic mutations in PALB2, CHEK2
and ATM could be associated with increased risk of cancers
other than breast cancer, as has been observed for BRCA1 and
BRCA2 and both ovarian and prostate cancers.14–17 However,
with the exception of pancreatic cancer in PALB2 carriers, there
is little evidence to support or refute the existence of such
associations, although a few individually striking pedigrees have
been observed.4 8 18–20
In this study we selected rare genetic variants on the basis
that they had been observed in breast cancer candidate gene
case-control screening projects involving PALB2, CHEK2 or
ATM. These included three rare variants in PALB2: the protein
truncating variants c.1592delT (p.Leu531Cysfs)4 and c.3113
G>A (p.Trp1038*)6 and the missense variant c.2816T>G, (p.
Leu939Trp), six rare missense variants in CHEK2: c.349A>G
(p.Arg117Gly) and c.1036C>T (p.Arg346Cys) predicted to be
deleterious on the basis of evolutionary conservation,11
c.538C>T (p.Arg180Cys), c.715G>A (p.Glu239Lys), c.1312G>T
(p.Asp438Tyr) and c.1343T>G (p.Ile448Ser) and ATM
c.7271T>G (p.Val2424Gly).7 We assessed the association of
these variants with breast, ovarian and prostate risk by case-
control analyses in three large consortia participating in the
Collaborative Oncological Gene-environment Study.21 22
METHODS
Participants
Participants were drawn from studies participating in three con-
sortia as follows:
The Breast Cancer Association Consortium (BCAC), involving
a total of 48 studies: 37 of women from populations with
predominantly European ancestry (42 671 cases and 42 164
controls), 9 of Asian women (5795 cases and 6624 controls)
and 2 of African-American women (1046 cases and 932 con-
trols). All cases had invasive breast cancer. The majority of
studies were population-based or hospital-based case-control
studies, but some studies of European women oversampled cases
with a family history or with bilateral disease (see online
supplementary table S1). Overall, 79% of BCAC cases with
known Estrogen Recptor (ER) status (23% missing) are ER-
positive. The proportion of cases selected by family history that
are ER-positive is 78% (38% missing).
The Prostate Cancer Association Group to Investigate Cancer
Associated Alterations in the Genome (PRACTICAL) involving a
total of 26 studies: 25 included men with European ancestry
(22 301 cases and 22 320 controls) and 3 included African-
American men (623 cases and 569 controls). The majority of
studies were population-based or hospital-based case-control
studies (see online supplementary table S2).
The Ovarian Cancer Association Consortium (OCAC), in-
volving a total of 46 studies. Some studies were case-only and
their data were combined with case-control studies from the
same geographical region (leaving 36 study groupings). Of these
groupings, 33 included women from populations with predomin-
antly European ancestry (16 287 cases (14 542 with invasive
disease) and 23 491 controls), 25 included Asian women (813
cases (720 with invasive disease) and 1574 controls), 17 included
African-American women (186 cases (150 with invasive disease)
and 200 controls) and 29 included women of other ethnic origin
(893 cases (709 with invasive disease) and 864 controls). The
majority of studies were population-based or hospital-based case-
control studies (see online supplementary table S3).
Details regarding sample quality control have been published
previously.22 23 All study participants gave informed consent
and all studies were approved by the corresponding local ethics
committees (see online supplementary tables S1–S3).
Variant selection
We selected for genotyping 13 rare mutations that had been
observed in population-based case-control mutation screening
studies. These variants were PALB2 (c.1592delT, p.
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Leu531Cysfs;4 5 10 c.2323C>T p.Gln775*;20 c.2816T>G, p.
Leu939Trp;2 20 c.3113G>A, p.Trp1038*;2 6 20 c.3116delA, p.
Asn1039IIefs;2 6 20 c.3549C>G, p.Tyr1183*2), CHEK2
(c.349A>G, p.ArgR117Gly; c.538C>T, p.Arg180Cys;
c.715G>A p.Glu239Lys; c.1036C>T, p.Arg346Cys; c.1312G>T,
p.Asp438Tyr; c.1343T>G, p.Ile448Ser)11 and ATM (c.7271T>G,
p.Val2424Gly)7 13 24 see table 1. A DNA sample carrying each of
these variants was included in a plate of control DNAs that was
distributed to each genotyping centre to assist with quality control
and genotype calling.
Genotyping
Three PALB2 variants c.2323C>T (p.Gln775*), c.3116delA
(p.Asn1039IIefs) and c.3549C>G (p.Tyr1183*) were unable to
be designed for measurement on the custom Illumina iSelect
genotyping array and were not considered further (table 1).
Genotyping was conducted using a custom Illumina Inﬁnium
array (iCOGS) in four centres, as part of a multiconsortia collab-
oration as described previously.22 Genotypes were called using
Illumina’s proprietary GenCall algorithm and then, for the data
generated from the rare variant probes, manually conﬁrmed
with reference to the positive control sample. Two per cent of
samples were provided in duplicate by all studies and 270
HapMap2 samples were genotyped in all four genotyping
centres. Subjects with an overall call rate <95% were excluded.
Plates with call rates <90% were excluded on a variant-by-
variant basis. Cluster plots generated for all of the 10 rare var-
iants were manually checked to conﬁrm automated calls (see
online supplementary ﬁgure S1).
Statistical methods
The association of each variant with breast, prostate and ovarian
cancer risk was assessed using unconditional logistic regression
to estimate ORs for carriers versus non-carriers, adjusting for
study (categorical). p Values were determined by the likelihood
ratio test comparing models with and without carrier status as a
covariate. We also applied conditional logistic regression, deﬁn-
ing risk sets by study, and found that this made no difference to
the OR estimates, CIs or p values to two signiﬁcant ﬁgures;
since model convergence was a problem for this latter regression
analysis, all subsequent analyses were based on unconditional
logistic regression. For the main analyses of breast cancer risk in
European women, we also included as covariates the ﬁrst six
principal components, together with a seventh component spe-
ciﬁc to one study (Leuven Multidisciplinary Breast Centre
(LMBC)) for which there was substantial inﬂation not accounted
for by the components derived from the analysis of all studies.
Addition of further principal components did not reduce inﬂa-
tion further. Data from all breast cancer studies were included
to assess statistical signiﬁcance. Data from cases selected for
inclusion based on personal or family history of breast cancer
were excluded in order to obtain unbiased OR estimates for the
general population of white European women (leaving 37 039
cases and 38 260 controls from 32 studies). Multiple testing was
adjusted for using the Benjamini-Hochberg procedure to control
the false discovery rate, with a signiﬁcance threshold of 0.05.25
Reported p values are unadjusted unless otherwise stated.
Reported CIs are all nominal. We included two race-speciﬁc
principal components in each of the main breast cancer analyses
of Asian and African-American women. Similar analyses were
conducted using the data from PRACTICAL and OCAC, consist-
ent with those used previously.23 26 All analyses were carried
out using Stata: Release V.10 (StataCorp, 2008).
RESULTS
PALB2
In BCAC, PALB2 c.1592delT (Leu531Cysfs) was only observed
in 35 cases and 6 controls, all from four studies from Sweden
and Finland (Helsinki Breast Cancer Study (HEBCS), Kuopio
Breast Cancer Project (KBCP), Oulu Breast Cancer Study
(OBCS) and Karolinska Mammography Project for Risk
Prediction Breast Cancer (pKARMA); see online supplementary
Table 1 Rare genetic variants included in the iCOGS array.
Gene Variant* Amino acid* dbSNP rs
Breast cancer risk estimates
Align-GVGD Reference(s) Designed‡ GenotypedOR (95% CI)
Penetrance†
(95% CI)
PALB2 c.1592delT p.Leu531Cysfs rs180177102 3.94 (1.5-12.1)§ 40% (17–77) na 4, 5, 10 Yes Yes
c.2323C>T p.Gln775* rs180177111 na 25, 26 No No
c.2816T>G p.Leu939Trp rs45478192 C55 20 Yes Yes
c.3113G>A p.Trp1038* rs180177132 95% (44–100) na 2, 6, 20 Yes Yes
c.3116delA p.Asn1039Ilefs rs180177133 na 2 No No
c.3549C>G p.Tyr1183* rs118203998 na 2 No No
CHEK2 c.349A>G p.Arg117Gly rs28909982 8.75 (1.06–72.2)¶ C65 11 Yes Yes
c.538C>T p.Arg180Cys rs77130927 2.47 (0.45–13.49)** C25 11 Yes Yes
c.715G>A p.Glu239Lys rs121908702 1.82 (0.62–5.34)†† C15 11 Yes Yes
c.1036C>T p.Arg346Cys na 8.75 (1.06–72.2)¶ C65 11 Yes Yes
c.1312G>T p.Asp438Tyr na 2.47 (0.45–13.49)** C25 11 Yes Yes
c.1343T>G p.Ile448Ser rs17886163 1.82 (0.62–5.34)†† C15 11 Yes Yes
ATM c.7271T>G p.Val2424Gly rs28904921 52% (28–80) C65 7, 13, 23, 27 Yes Yes
*Human Genome Variation Society (HGVS); reference sequences PALB2, NM_024675.3, NP_078951.2; CHEK2, NM_007194.3, NP_009125.1; ATM, NM_000051.3, NP_000042.3.
†Age-specific cumulative risk of breast cancer to age 70 years.5–7
‡Able to be designed for measurement on the custom Illumina iSelect genotyping array.21 22
§Breast cancer cases unselected for family history of breast cancer.4
¶OR estimated in a combined group of C65 CHEK2 variants.11
**OR estimated in a combined group of C25 CHEK2 variants.11
††OR estimated in a combined group of C15 CHEK2 variants.11
na, not available.
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table S1), giving strong evidence of association with breast
cancer risk (p=7.1×10−5); the OR estimate was 4.52 (95% CI
1.90 to 10.8) based on all studies and 3.44 (95% CI 1.39 to
8.52) based on unselected cases and controls (table 2). We also
found evidence of heterogeneity by ER status (p=0.0023), the
association being stronger for ER-negative disease (OR 6.49
(95% CI 2.17 to 19.4) versus 2.24 (95% CI 1.05 to 7.24) for
ER-positive disease).
PALB2 c.3113G>A (p.Trp1038*) was identiﬁed in 44 cases
and 8 controls from nine BCAC studies. Only one carrier of the
variant was of non-European origin. Strong evidence of associ-
ation with breast cancer risk was observed (p=6.9×10−8), with
an estimated OR of 5.93 (95% CI 2.77 to 12.7) based on all
studies and 4.21 (95% CI 1.85 to 9.61) based on unselected
cases and controls. There was no evidence of a differential asso-
ciation by ER status (p=0.15).
Based on unselected cases, the estimated OR associated with
carrying either of these PALB2 variants (c.1592delT or
c.3113G>A) was 3.85 (95% CI 2.09 to 7.09).
PALB2 c.2816T>G (p.Leu939Trp) was identiﬁed in 150
cases and 145 controls and there was no evidence of association
with risk of breast cancer. There was no evidence of association
with risk of prostate or ovarian cancer for any of the three
PALB2 variants (see tables 3 and 4).
Table 2 Summary results from Breast Cancer Association Consortium studies of white Europeans (42 671 invasive breast cancer cases and
42 164 controls)
Variant
Frequency*
Controls
Frequency*
Cases OR (95% CI)
LRT
p Value OR† (95% CI)
LRT
p Value†
PALB2§
c.1592delT (p.Leu531Cysfs) 0.00014 0.00082 4.52 (1.90 to 10.8) 7.1×10−5 3.44 (1.39 to 8.52) 0.003
c.2816T>G (p.Leu939Trp) 0.00342 0.00352 1.05 (0.83 to 1.32) 0.70 1.03 (0.80 to 1.32) 0.82
c.3113G>A (p.Trp1038*) 0.00019 0.00101 5.93 (2.77 to 12.7) 6.9×10−8 4.21 (1.84 to 9.60) 1.2×10−4
CHEK2
c.349A>G (p.Arg117Gly) 0.00043 0.00103 2.26 (1.29 to 3.95) 0.003 2.03 (1.10 to 3.73) 0.020
c.538C>T (p.Arg180Cys) 0.00337 0.00370 1.33 (1.05 to 1.67) 0.016 1.34 (1.06 to 1.70) 0.015
c.715G>A (p.Glu239Lys) 0.00021 0.00035 1.70 (0.73 to 3.93) 0.210 1.47 (0.60 to 3.64) 0.40
c.1036C>T (p.Arg346Cys) 0.00005 0.00021 5.06 (1.09 to 23.5) 0.017 3.39 (0.68 to 16.9) 0.11
c.1312G>T (p.Asp438Tyr) 0.00078 0.00082 1.03 (0.62 to 1.71) 0.910 0.87 (0.49 to 1.52) 0.62
c.1343T>G (p.Ile448Ser)‡ 0.00002 0 – – – –
ATM
c.7271T>G (p.Val2424Gly) 0.00002 0.00028 11.6 (1.50 to 89.9) 0.0012 11.0 (1.42 to 85.7) 0.0019
*Proportion of subjects carrying the variant.
†Excluding women from five studies that selected all cases based on family history or bilateral disease and the subset of selected cases from other studies (based on 34 488 unselected
cases and 34 059 controls).
‡CHEK2 c.1343T>G (p.Ile448Ser) was only observed in one control and no cases of white European origin.
§PALB2 c.3113G>A (p.Trp1038*) only observed in the UK, Australia, the USA and Canada. PALB2 c.1592delT (p.Leu531Cysfs) only observed in Finland and Sweden.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.
Table 3 Summary results from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome studies for
white European men* (22 301 prostate cancer cases and 22 320 controls)
Variant
Frequency†
Controls
Frequency†
Cases OR (95% CI)
LRT
p Value
PALB2
c.1592delT (p.Leu531Cysfs) 0.00018 0.00031 2.06 (0.59 to 7.11) 0.24
c.2816T>G (p.Leu939Trp) 0.00354 0.00381 0.95 (0.69 to 1.29) 0.73
c.3113G>A (p.Trp1038*) 0.00045 0.00027 0.49 (0.18 to 1.36) 0.16
CHEK2‡
c.349A>G (p.Arg117Gly) 0.00063 0.00081 1.46 (0.71 to 3.02) 0.30
c.538C>T (p.Arg180Cys) 0.00341 0.00296 1.02 (0.73 to 1.44) 0.90
c.715G>A (p.Glu239Lys) 0.00018 0.00027 1.47 (0.41 to 5.35) 0.55
c.1036C>T (p.Arg346Cys) 0.00018 0.00022 1.07 (0.28 to 4.07) 0.93
c.1312G>T (p.Asp438Tyr) 0.00049 0.00103 2.21 (1.06 to 4.63) 0.03
c.1343T>G (p.Ile448Ser) 0 0.00009 – –
c.1343T>G (Africans§) 0.019 0.057 3.03 (1.53 to 6.03) 0.001
ATM
c.7271T>G (p.Val2424Gly) 0.00004 0.00027 4.37 (0.52 to 36.4) 0.17
*For white European men, unless otherwise indicated.
†Proportion of subjects carrying the variant.
‡CHEK2 c.1343T>G (p.Ile448Ser) was the only CHEK2 variant observed in African men and was identified in two cases and no controls of white European origin.
§Based on data from 623 and 569 African-American cases and controls, respectively.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.
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CHEK2
CHEK2 c.349A>G (p.Arg117Gly) was identiﬁed in 44 cases and
18 controls in studies participating in BCAC; all of these women
were of European origin. We found evidence of association with
breast cancer (p=0.003), with little change in the OR after exclud-
ing selected cases (OR 2.03 (95% CI 1.10 to 3.73)).
CHEK2 c.538C>T (p.Arg180Cys) was identiﬁed in 158
breast cancer cases and 142 controls in studies of white
Europeans. Evidence of association with breast cancer risk
(p=0.016) was observed, with an unbiased OR estimate of 1.34
(95% CI 1.06 to 1.70). A consistent OR estimate was observed
for Asian women, based on 45 case and 45 control carriers (OR
1.16 (95% CI 0.75 to 1.76)).
CHEK2 c.715G>A (p.Glu239Lys) mutations were identiﬁed
in 15 cases and 9 controls, all European women participating in
BCAC and no evidence of association with risk of breast cancer
was observed (p=0.21).
CHEK2 c.1036C>T (p.Arg346Cys) was identiﬁed in nine
cases from seven studies and two controls from two different
studies in BCAC (neither control carrier was from a study that had
case carriers), all of European origin. We found evidence of associ-
ation with breast cancer risk (p=0.017) with reduced OR estimate
of 3.39 (95% CI 0.68 to 16.9) after excluding selected cases.
None of the above four CHEK2 variants (CHEK2 c.349A>G
(p.Arg117Gly); c.538C>T (p.Arg180Cys); c.715G>A (p.
Glu239Lys) and c.1036C>T (p.Arg346Cys)) were found to be
associated with an increased risk of prostate or ovarian cancer
(tables 3 and 4). CHEK2 variant c.1312G>T (p.Asp438Tyr)
was not associated with risk of breast cancer for European
women (p=0.91). Variant c.1343T>G (p.Ile448Ser) was not
observed in any breast cancer cases of European or Asian origin.
It was detected in 48 cases and 29 controls of African origin,
giving weak evidence of association (OR 1.52 (95% CI 0.95 to
2.43, p=0.083)). CHEK2 c.1312G>T (p.Asp438Tyr) was identi-
ﬁed in 23 cases and 11 controls from PRACTICAL, all European,
providing evidence of association with prostate cancer risk (OR
2.21 (95% CI 1.06 to 4.63, p=0.030)). CHEK2 c.1343T>G (p.
Ile448Ser) was observed in 35 cases and 11 controls, all African,
participating in PRACTICAL and was also associated with an
increased risk of prostate cancer (OR 3.03 (95% CI 1.53 to 6.03,
p=0.00059)). There was no evidence that these CHEK2 variants
were associated with risk of ovarian cancer (table 4).
ATM
ATM c.7271T>G (p.Val2424Gly) was identiﬁed in 12 cases
and 1 control in studies participating in BCAC, all of European
origin, giving evidence of association with breast cancer risk
(p=0.0012). The OR estimate based on unselected studies was
11.0 (95% CI 1.42 to 85.7). There was no evidence of associ-
ation of this variant with prostate or ovarian cancer risk (see
tables 3 and 4).
DISCUSSION
The present report adds to an accumulating body of evidence
that at least some rare variants in so-called ‘moderate-risk’ genes
are associated with an increased risk of breast cancer that is of
clinical relevance.
These ﬁndings are presented at a time when detailed informa-
tion about variants in these genes is becoming more readily avail-
able via the translation of diagnostic genetic testing from Sanger
sequencing-based testing platforms to MPS platforms that test
panels of genes in single assays.27–29 The vast majority of infor-
mation about PALB2, CHEK2 and ATM, variants generated from
these new testing platforms is not being used in clinical genetics
services due to lack of reliable estimates of the cancer risk asso-
ciated with individual variants, or groups of variants, in each
gene. Previous analyses have been largely based on selected fam-
ilies, relying on data on the segregation of the variant. The
present study is by far the largest to take a case-control approach.
Consistent with previous reports,5–7 9 11–13 PALB2 c.3113G>A
(p.Trp1038*), PALB2 c.1592delT (p.Leu531Cysfs) and ATM
c.7271T>G (p.Val2424Gly) were found to be associated with
substantially increased risk of breast cancer all with associated
relative risk estimates of 3.44 or greater.
The estimates for the two loss-of-function PALB2 variants
(c.1592delT and c.3113G<A) were consistent with each other
and with estimates based on segregation analysis.5 6 9 We found
no evidence of association with breast cancer for PALB2
c.2816T>G (p.Leu939Trp), with an upper 95% conﬁdence
limit excluding an OR >1.5 which is notable given the
Table 4 Summary results from the Ovarian Cancer Association Consortium studies for white European women (14 542 invasive ovarian cancer
cases and 23 491 controls)
Variant
Frequency*
Controls
Frequency*
Cases OR (95% CI)
LRT
p Value
PALB2
c.1592delT (p.Leu531Cysfs) 0.00004 0.00012 2.50 (0.21 to 29.1) 0.45
c.2816T>G (p.Leu939Trp) 0.00413 0.00399 0.96 (0.69 to 1.34) 0.81
c.3113G>A (p.Trp1038*) 0.00034 0.00031 1.34 (0.36 to 4.97) 0.66
CHEK2
c.349A>G (p.Arg117Gly) 0.00038 0.00031 1.07 (0.32 to 3.60) 0.92
c.538C>T (p.Arg180Cys) 0.00128 0.00160 1.49 (0.83 to 2.67) 0.18
c.715G>A (p.Glu239Lys) 0.00021 0.00037 1.47 (0.42 to 5.22) 0.54
c.1036C>T (p.Arg346Cys)‡ 0 0 – –
c.1312G>T (p.Asp438Tyr) 0.00081 0.00074 0.92 (0.42 to 1.99) 0.83
c.1343T>G (p.Ile448Ser) 0.00009 0 – –
ATM
c.7271T>G (p.Val2424Gly) 0 0.00012 – –
*Proportion of subjects carrying the variant.
‡c.1036C>T (p.Arg346Cys) was not observed in any sample.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.
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Align-Grantham Variation Granthan Deviation (Align-GVGD)
score and the observed impact on protein function.30
The estimate for ATM c.7271T>G (p.Val2424Gly) was also
consistent with that found by segregation analysis.7 13 The sub-
stantial increased risk of breast cancer associated with ATM
c.7271T>G (p.Val2424Gly) could be due to the reduction in
kinase activity (with near-normal protein levels) observed for
ATM p.Val2424Gly,31 thus this variant is likely to be acting as a
dominant negative mutation.32
In contrast, we found no evidence of an association with risk
of prostate or ovarian cancer with any of these three variants:
however, the conﬁdence limits were wide; based on the upper
95% conﬁdence limit we could exclude an OR of >1.4 for
prostate cancer for the loss-of-function PALB2 c.3113G>A and
1.9 for c.1592delT and c.3113G>A combined.
We analysed six rare missense variants in CHEK2. Two of
these (CHEK2 c.349A>G (p.Arg117Gly; rs28909982) and
c.1036C>T (p.Arg346Cys)) had evidence of a signiﬁcant
impact on the protein based on in silico prediction. We pro-
posed these variants for inclusion in the iCOGS design as they
had been identiﬁed in 3/1242 cases and 1/1089 controls and
3/1242 cases and 0/1089 controls, respectively, in a population-
based case-control mutation screening study of CHEK2.11 In
that study, Le Calvez-Kelm et al, estimated an OR of 8.75 (95%
CI 1.06 to 72.2) for variants with an Align-GVGD score C65
(based on nine cases and one control). The current analysis pro-
vides conﬁrmatory evidence of this association in a much larger
sample (OR 2.18 (95% CI 1.23 to 3.85)) including 40 unse-
lected case and 18 control carriers. The evidence that CHEK2 is
a breast cancer susceptibility gene is largely based on studies of
protein truncating variants, in particular CHEK2 1100delC.33
Reports of the association of the missense variant I157T, (C15)
and breast cancer risk have been conﬂicting but a large
meta-analysis involving 15 985 breast cancer cases and 18 609
controls estimated a modest OR of 1.58 (95% CI 1.42 to
1.75).34 We also found evidence (p=0.015) of an association
for c.538C>T (Align-GVGD C25); OR 1.34 (95% CI 1.06 to
1.70), a risk comparable to I157T.
The p values reported above have not been adjusted for mul-
tiple testing. This was not considered appropriate for the asso-
ciations with breast cancer risk of PALB2 c.1592delT,
c.3113G>A and ATM c.7271T>G because these associations
had previously been reported; our aim was to more precisely
estimate the associated relative risks. All three associations with
breast cancer risk reported for CHEK2 variants remained statis-
tically signiﬁcant after adjusting for the other tests conducted in
relation to breast cancer risk, but not after correcting for all
tests for all cancers. Nevertheless, the ﬁndings for CHEK2
c.349A>G and c.1036C>T conﬁrmed those reported previ-
ously, although collectively. The association observed with
CHEK2 c.538C>Trequires independent replication.
Do this approach and new data have an impact on clinical
recommendations for women and families carrying these rare
genetic variants? Although age-speciﬁc cumulate risks for cancer
are more informative for genetic counselling and clinical man-
agement of carriers, our study provides information that is rele-
vant to clinical recommendations. As discussed in Easton et al,35
a relative risk of 4 will place a woman in a ‘high-risk’ category (in
the absence of any other risk factor) and a relative risk between 2
and 4 will place a woman in this category if other risk factors are
present. Thus, several of the variants included in this report
(PALB2 c.1592delT; c.3113G>A ATM c.7271T>G) would place
the carrier in a high-risk group, especially if other risk factors,
such as a family history, are present. The high level of breast
cancer risk associated with PALB2 c.1592delT and c.3113G>A
reported here is consistent with the penetrance estimate reported
for a group of loss-of-function mutations in PALB29 and has an
advantage in terms of clinical utility that the estimates in this
study have been made at a mutation-speciﬁc level. Therefore, this
work provides important information for risk reduction recom-
mendations (such as prophylactic mastectomy and potentially
salpingo-oophorectomy) for carriers of these variants. However,
further prospective research is required to characterise these risks
and to understand the potential of other risk-reducing strategies
such as salpingo-oophorectomy and chemoprevention.
The consistency of the relative risk estimates with those derived
through family based studies supports the hypothesis that these
variants combine multiplicatively with other genetic loci and
familial risk factors; this information is critical for deriving com-
prehensive risk models. Even with very large sample sizes such as
those studied here, however, it is still only possible to derive indi-
vidual risk estimates for a limited set of variants, and even for
these variants the estimates are still imprecise. This internationally
collaborative approach also has limited capacity to improve risk
estimates for rare variants that are only observed in speciﬁc popu-
lations. Inevitably, therefore, risk models will depend on combin-
ing data across multiple variants, using improved in silico
predictions and potentially biochemical/functional evidence to
synthesise these estimates efﬁciently. It will also be necessary
develop counselling and patient management strategies that can
accommodate a multifactorial approach to variant classiﬁcation.
Author afﬁliations
1Genetic Epidemiology Laboratory, Department of Pathology, The University of
Melbourne, Melbourne, Australia
2Huntsman Cancer Institute, Salt Lake City, UT, USA
3Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational
Medicine Research Unit and Biocenter Oulu, University of Oulu, Nordlab Oulu, Oulu,
Finland
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN,
USA
5Department of Medical Genetics and National Institute for Health Research
Cambridge Biomedical Research Centre, University of Cambridge, and the
Department of Clinical Genetics, East Anglian Regional Genetics Service,
Addenbrooke’s Hospital
6Program in Cancer Genetics, Department of Human Genetics and Oncology, Lady
Davis Institute, and Research Institute, McGill University Health Centre, McGill
University, Montreal, Canada,
7Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
Care, University of Cambridge, Strangeways Laboratory, Worts Causeway,
Cambridge, UK
8Department of Genetics, University of Pretoria, South Africa
9Department of Obstetrics and Gynecology, University of Helsinki and Helsinki
University Central Hospital, Helsinki, Finland
10Centre for Epidemiology and Biostatistics, School of Population and Global Health,
The University of Melbourne, Melbourne, Australia,
11Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
12Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, 9000
Ghent, Belgium,
13Department of Pathology and Human Oncology and Pathogenesis Program,
Memorial Sloan-Kettering Cancer Center, New York, New York, USA
14Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of
Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori
(INT), Milan, Italy
15IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy
16Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam,
The Netherlands
17Australian Breast Cancer Tissue Bank, University of Sydney at the Westmead
Institute for Medical Research, NSW, Australia
18Centre for Cancer Research, University of Sydney at the Westmead Institute for
Medical Research, NSW, Australia
19Division of Molecular Medicine, Pathology North, Newcastle and University of
Newcastle, NSW, Australia
20University Breast Center Franconia, Department of Gynecology and Obstetrics,
University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg,
Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
806 Southey MC, et al. J Med Genet 2016;53:800–811. doi:10.1136/jmedgenet-2016-103839
Cancer genetics
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
21David Geffen School of Medicine, Department of Medicine Division of Hematology
and Oncology, University of California at Los Angeles, CA, USA
22Unit of Biostatistics, Department of Gynecology and Obstetrics, University Hospital
Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
23Institute of Human Genetics, University Hospital Erlangen, Friedrich Alexander
University Erlangen-Nuremberg, Erlangen, Germany
24Non-communicable Disease Epidemiology Department, London School of Hygiene
and Tropical Medicine, London, UK
25Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research,
London, UK
26Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre,
Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College
London, London, UK
27Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research
Centre, University of Oxford, UK and Oxford NIHR Biomedical Research Centre,
Headington, OX3 7LE
28Surgery, Lambe Institute for Translational Science, NUIGalway, University Hospital
Galway, Galway, Ireland
29Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg,
Germany
30National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany
31Molecular Epidemiology Group, German Cancer Research Center (DKFZ),
Heidelberg, Germany
32Inserm (National Institute of Health and Medical Research), CESP (Center for
Research in Epidemiology and Population Health), U1018, Environmental
Epidemiology of Cancer, Villejuif, France
33University Paris-Sud, UMRS 1018, Villejuif, France
34Copenhagen General Population Study, Herlev Hospital, Copenhagen University
Hospital, University of Copenhagen, Copenhagen, Denmark
35Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University
Hospital, University of Copenhagen, Copenhagen, Denmark
36Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital,
Copenhagen, Denmark
37Human Genetics Group, Human Cancer Genetics Program, Spanish National
Cancer Research Centre (CNIO), Madrid, Spain
38Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain
39Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain
40Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain
41Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain
42Department of Epidemiology, University of California Irvine, Irvine, California, USA
43Beckman Research Institute of City of Hope, Duarte, California, USA
44Department of Epidemiology, University of California Irvine, Irvine, California, USA
45Cancer Prevention Institute of California, Fremont, California, USA
46Division of Clinical Epidemiology and Aging Research, German Cancer Research
Center (DKFZ), Heidelberg, Germany
47Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg,
Germany
48German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
Heidelberg, Germany
49Saarland Cancer Registry, Saarbrücken, Germany
50Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart
51University of Tübingen, Tübingen, Germany
52Institute for Prevention and Occupational Medicine of the German Social Accident
Insurance, Institute of the Ruhr University, Bochum (IPA), Germany
53Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter
Krankenhaus, Bonn, Germany
54Department of Obstetrics and Gynecology, University of Helsinki and Helsinki
University Central Hospital, Helsinki, Finland
55Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki,
Finland
56Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
57Department of Radiation Oncology, Hannover Medical School, Hannover, Germany
58N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk,
Belarus
59Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm,
Sweden
60Department of Oncology – Pathology, Karolinska Institutet, Stockholm, Sweden
61School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine,
and Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland
62Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
Kuopio, Finland
63School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern
Finland, Kuopio, Finland
64Biocenter Kuopio, Cancer Center of Eastern Finland, Kuopio University Hospital,
Kuopio, Finland
65QIMR Berghofer Medical Research Institute, Brisbane, Australia
66Research Department, Peter MacCallum Cancer Centre and The Sir Peter MacCallum
Department of Oncology, University of Melbourne, Victoria, Australia
67Vesalius Research Center (VRC), VIB, Leuven, Belgium
68Laboratory for Translational Genetics, Department of Oncology, University of Leuven,
Leuven, Belgium
69University Hospital Gasthuisberg, Leuven, Belgium
70Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
Heidelberg, Germany
71Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for
Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg,
Germany
72Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
73Anatomical Pathology, The Alfred Hospital, Melbourne, Australia
74Department of Preventive Medicine, Keck School of Medicine, University of Southern
California, Los Angeles, CA, USA
75Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, HI,
USA
76Department of Genetics, Institute for Cancer Research, Oslo University Hospital,
Radiumhospitalet, Oslo, Norway
77Faculty of Medicine (Faculty Division Ahus), University of Oslo (UiO), Norway
78Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville,
TN, USA
79Program in Molecular and Genetic Epidemiology, Harvard School of Public Health,
Boston, MA, USA
80Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
81Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA, USA
82Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute of
Mount Sinai Hospital, Toronto, Ontario, Canada
83Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
84Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of
Mount Sinai Hospital, Toronto, Ontario, Canada
85Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto,
Toronto, Ontario, Canada
86Department of Laboratory Medicine and Pathobiology, University of Toronto,
Toronto, ON, Canada
87Laboratory Medicine Program, University Health Network, Toronto, Ontario;
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto,
ON, Canada
88Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland
89Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland
90Department of Pathology, Oulu University Hospital, University of Oulu, Oulu,
Finland
91Department of Surgical Oncology, Leiden University Medical Center, 2300 RC
Leiden, The Netherlands
92Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den
Hoed Cancer Centre, Rotterdam, The Netherlands
93The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer
Research, London, SW3 6JB, UK
94Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Rockville, Maryland, USA
95Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie
Memorial Cancer Center & Institute of Oncology, Warsaw, Poland
96Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
Stockholm 17177, Sweden
97Faculty of Medicine, University of Southampton (UoS), Southampton UK
98Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
Institute, Rotterdam, The Netherlands
99Department of Clinical Genetics, Family Cancer Clinic, Erasmus University
Medical Center, Rotterdam, The Netherlands
100Department of Surgical Oncology, Family Cancer Clinic, Erasmus University
Medical Center, Rotterdam, The Netherlands
101Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
Stockholm 17177, Sweden
102Human Genetics Division, Genome Institute of Singapore, Singapore 138672,
Singapore
103Shefﬁeld Cancer Research, Department of Oncology, University of Shefﬁeld,
Shefﬁeld, UK
104Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
Cambridge, Cambridge, UK
105Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
Heidelberg, Germany
106Institute of Human Genetics, Pontiﬁcia Universidad Javeriana, Bogota, Colombia
107Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany
108Institute of Pathology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
109Department of Genetics and Pathology, Pomeranian Medical University,
Szczecin, Poland
110Postgraduate School of Molecular Medicine, Warsaw Medical University,
Warsaw, Poland
Southey MC, et al. J Med Genet 2016;53:800–811. doi:10.1136/jmedgenet-2016-103839 807
Cancer genetics
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
111Department of Molecular Virology, Immunology and Medical Genetics,
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
112Roswell Park Cancer Institute, Buffalo, New York, USA
113Molecular Diagnostics Laboratory, IRRP, National Centre for Scientiﬁc Research
"Demokritos", Aghia Paraskevi Attikis, Athens, Greece
114Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
115Division of Breast Cancer Research, Institute of Cancer Research, London, UK
116Centre d’innovation Genome Quebec et University McGill Montreal Quebec, Canada
117McGill University, Montreal, Quebec, Canada
118Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Quebec Research
Center. Laval University, Quebec, Canada
119The Institute of Cancer Research, London, SM2 5NG, UK
120Royal Marsden NHS Foundation Trust, Fulham, London, SW3 6JJ, UK
121University of Warwick, Coventry, UK
122Department of Medical Epidemiology and Biostatistics, Karolinska Institute,
Stockholm, Sweden
123Department of Medical Biochemistry and Genetics, University of Turku, and Tyks
Microbiology and Genetics, Department of Medical Genetics, Turku University
Hospital, Turku, Finland
124Institute of Biomedical Technology/BioMediTech, University of Tampere, Tampere,
Finland
125Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University
Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark
126Department of Human Genetics University of Utah, Salt Lake City, UT, USA and
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University
Hospital, University of Copenhagen, Copenhagen, Denmark
127Cancer Epidemiology Unit, Nufﬁeld Department of Population Health, University
of Oxford, Oxford, UK
128Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Box 279,
Addenbrooke’s Hospital, Hills Road, Cambridge, UK and Cancer Research UK
Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK
129Professor of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley
Road, Bristol BS8 2PS
130Nufﬁeld Department of Surgical Sciences, Old Road Campus Research
Building (off Roosevelt Drive), University of Oxford, Headington, Oxford, OX3 7DQ
131Cambridge Institute of Public Health, University of Cambridge, Forvie Site,
Robinson Way, Cambridge CB2 0SR
132Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
Seattle, Washington, USA
133Department of Epidemiology, School of Public Health, University of Washington,
Seattle, Washington, USA
134International Epidemiology Institute, 1455 Research Blvd., Suite 550, Rockville,
MD 20850
135Department of Obstetrics, Gynecology and Reproductive Sciences, University of
Pittsburgh School of Medicine, Pittsburgh, PA, USA
136Department of Urology, University Hospital Ulm, Germany
137Institute of Human Genetics University Hospital Ulm, Germany
138Brigham and Women’s Hospital/Dana-Farber Cancer Institute, 45 Francis Street-
ASB II-3, Boston, MA 02115
139Washington University, St Louis, Missouri
140International Hereditary Cancer Center, Department of Genetics and Pathology,
Pomeranian Medical University, Szczecin, Poland
141Division of Genetic Epidemiology, Department of Medicine, University of Utah
School of Medicine
142Division of Cancer Prevention and Control, H. Lee Mofﬁtt Cancer Center, 12902
Magnolia Dr., Tampa, Florida, USA
143Molecular Medicine Center and Department of Medical Chemistry and
Biochemistry, Medical University – Soﬁa, 2 Zdrave St, 1431, Soﬁa, Bulgaria
144Australian Prostate Cancer Research Centre-Qld, Institute of Health and
Biomedical Innovation and Schools of Life Science and Public Health, Queensland
University of Technology, Brisbane, Australia
145Department of Genetics, Portuguese Oncology Institute, Porto, Portugal and
Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
146University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-
Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-
EMN, Universitaetsstrasse 21-23, 91054 Erlangen, Germany
147University Hospital Erlangen, Institute of Pathology, Friedrich-Alexander-University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
Universitaetsstrasse 21-23, 91054 Erlangen, German
148Vesalius Research Center, VIB, Leuven, Belgium
149Laboratory for Translational Genetics, Department of Oncology, University of
Leuven, Belgium
150Department of Epidemiology, The Geisel School of Medicine at Dartmouth,
Lebanon, NH, USA
151Department of Epidemiology, The Geisel School of Medicine at Dartmouth,
Hannover, NH, USA
152Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson
Cancer Research Center, Seattle, WA, USA
153Department of Epidemiology, University of Washington, Seattle, WA, USA
154German Cancer Research Center, Division of Cancer Epidemiology, Heidelberg,
Germany
155Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany
156Department of Gynecological Oncology, Roswell Park Cancer Institute,
Buffalo, NY
157Cancer Epidemiology Program, University of Hawaii Cancer Center, Hawaii, USA
158Department of Pathology, Kapiolani Medical Center for Women and Children, John
A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii 96826, USA
159Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute,
Cedars-Sinai Medical Center, Los Angeles, California, USA
160Community and Population Health Research Institute, Department of Biomedical
Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
161Department of Gynecology and Obstetrics, Friedrich Schiller University, Jena
University Hospital, Jena, Germany
162Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover,
Germany
163Department of Pathology, Helsinki University Central Hospital, Helsinki, 00029
HUS, Finland
164University of Pittsburgh Department of Obstetrics, Gynecology and Reproductive
Sciences and Ovarian Cancer Center of Excellence Pittsburgh PA USA
165University of Pittsburgh Department of Epidemiology, University of Pittsburgh
Graduate School of Public Health and Womens Cancer Research Program, Magee-
Womens Research Institute and University of Pittsburgh Cancer Institute Pittsburgh PA
USA
166The University of Texas School of Public Health, Houston, TX, USA
167Department of Cancer Prevention and Control, Roswell Park Cancer Institute,
Buffalo, NY
168Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang.
Huyssens-Stiftung/ Knappschaft GmbH, Essen, Germany
169Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken
Wiesbaden, Wiesbaden, Germany
170Tuebingen University Hospital, Department of Women’s Health, Tuebingen,
Germany
171Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute,
Cedars-Sinai Medical Center, Los Angeles, California
172Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center,
Copenhagen, Denmark
173Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark
174Molecular Unit, Department of Pathology, Herlev Hospital, University of
Copenhagen, Copenhagen, Denmark
175Unit of Medical Genetics, Department of Preventive and Predictive Medicine,
Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy
176Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO),
Milan, Italy
177Department of Experimental Oncology, Istituto Europeo di Oncologia (IEO), Milan,
Italy and Cogentech Cancer Genetic Test Laboratory, Milan, Italy
178University of Kansas Medical Center, Kansas City, KS, USA
179Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
180College of Pharmacy and Health Sciences, Texas Southern University, Houston,
Texas, USA
181Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer
Center, Houston, Texas, USA
182Department of Epidemiology, The University of Texas MD Anderson Cancer Center,
Houston, Texas, USA
183Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer
Center, New York, NY, USA
184Department of Obstetrics and Gynecology, Duke University Medical Center,
Durham, North Carolina, USA
185Department of Statistical Science, Duke University, Durham, North Carolina, USA
186Department of Surgery, Duke University Medical Center, Durham, North Carolina,
USA
187Cancer Prevention, Detection & Control Research Program, Duke Cancer Institute,
Durham, North Carolina, USA
188Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital,
Boston, Massachusetts, USA
189Channing Division of Network Medicine, Brigham and Women’s Hospital and
Harvard Medical School
190Department of Epidemiology, Harvard TH Chan School of Public Health, Boston,
Massachusetts, USA
191Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey,
The State University of New Jersey, New Brunswick, NJ, USA
192Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
Center, New York, NY, USA
193Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen,
Norway
194Centre for Cancer Biomarkers, Department of Clinical Sciences, University of
Bergen, Bergen, Norway
808 Southey MC, et al. J Med Genet 2016;53:800–811. doi:10.1136/jmedgenet-2016-103839
Cancer genetics
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
195Radboud university medical center, Department of Gynaecology, Nijmegen,
Netherlands
196Radboud university medical centre, Radboud Institute for Health Sciences,
Nijmegen, Netherlands
197Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
198Department of Obstetrcs & Gynecology, Oregon Health & Science University
199Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon,
USA
200Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver,
BC, Canada
201Department of Biomedical Physiology and Kinesiology, Simon Fraser University,
Burnaby, BC Canada
202Department of Public Health Sciences, College of Medicine, Medical University of
South Carolina, SC, USA
203Hollings Cancer Center, Medical University of South Carolina, SC, USA
204Division of Epidemiology and Biostatistics, Department of Internal Medicine,
University of New Mexico, Albuquerque, New Mexico, USA
205Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada
206International Hereditary Cancer Center, Department of Genetics and Pathology,
Pomeranian Medical University, Szczecin, Poland
207Department of Gynecological Surgery and Gynecological Oncology of Adults and
Adolescents, Pomeranian Medical University, Szczecin, Poland
208Gyn Clinic, Rigshospitalet, University of Copenhagen, Denmark
209Department of Pathology, Rigshospitalet, University of Copenhagen, Denmark
210Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark
211Department of Oncology, University of Cambridge, Strangeways Research
laboratory, Cambridge, UK
212Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre,
St Andrews Place, East Melbourne
213Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer
Research Centre, Beatson Institute for Cancer Research, Glasgow, UK
214The Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer
Centre, 1053 Great Western Road, Glasgow, G12 0YN
215Department of Gynaecological Oncology, Glasgow Royal Inﬁrmary
216Department of Health Research and Policy - Epidemiology, Stanford University
School of Medicine, Stanford CA, USA
217Epidemiology Center, College of Medicine, University of South Florida, Tampa,
Florida, USA
218Public Health Ontario, Toronto, Canada
219Women’s College Research Institute, University of Toronto, Toronto, Ontario,
Canada
220Department of Cancer Epidemiology, Mofﬁtt Cancer Center, Tampa, FL, USA
221Department of Biostatistics and Bioinformatics, Mofﬁtt Cancer Center, Tampa,
FL, USA
222Women’s Cancer, Institute for Women’s Health, UCL, London, United Kingdom
223Department of Preventive Medicine, Keck School of Medicine, University of
Southern California Norris Comprehensive Cancer Center, Los Angeles, California,
USA
224Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer
Center, New York, New York, USA
225Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
226Department of Medicine, The University of Melbourne Health, Australia,
227The Royal Melbourne Hospital, Victoria 3050, Australia
228Cancer Epidemiology Centre, Cancer Council Victoria, Victoria, Australia
Acknowledgements The authors thank the following for their contributions to
this study: Qin Wang (BCAC), Lesley McGuffog, and Ken Ofﬁt (CIMBA), Andrew Lee,
and Ed Dicks and the staff of the Centre for Genetic Epidemiology Laboratory, staff
of the CNIO genotyping unit, Sylvie LaBoissière and Frederic Robidoux and the staff
of the McGill University and Génome Québec Innovation Centre, staff of the
Copenhagen DNA laboratory, and Sharon A Windebank, Christopher A Hilker, Jeffrey
Meyer and the staff of Mayo Clinic Genotyping Core Facility. The authors also thank
UM1 CA167552 (Willett) Cancer Epidemiology Cohort in Male Health Professionals,
P01 CA87969 (Stampfer) Dietary and Hormonal Determinants of Cancer in Women,
UM1 CA186107 (Stampfer) Long term multidisciplinary study of cancer in women:
The Nurses’ Health Study, R01CA141298 (Stampfer) Growth Factors and Lethal
Prostate Cancer Signature, NCI: K07-CA80668 DAMD17-02-1-0669 NIH/National
Center for Research Resources/General Clinical Research Center grant
MO1-RR000056, R01CA095023, P50-CA159981, NCI CCSG award P30-CA008748
(Memorial Sloan Kettering Cancer Center), Department of Defense
(W81XWH-07-0449), National Health and Medical Research Council of Australia
APP1029974 and APP1061177, Deutsche Krebshilfe (Maier), Wellcome Trust Centre
for Human Genetics from the Wellcome Trust (090532/Z/09/Z). The authors thank
the National Institute of Health Research for their support to The Institute of Cancer
Research and Royal Marsden NHS Foundation Trust, London, UK.
Contributors All authors provided DNA samples and/or data and have participated
in the Breast Cancer Association Consortium through attendance at regular meetings
and planning of the iCOGS experiment. Each author has made substantial
contribution through designing and coordinating the studies listed in the
supplemental material and therefore have made substantial contributions to the
conception or design of this work. Many authors played multiple roles across these
activities. Speciﬁcally, MCS conceived this study, worked to include the rare variants
on the iCOGS and drafted the manuscript. RLM led the statistical analysis and
drafted the paper. Members of the PALB2 interest group, MCS, DEG, RW, KP, FC,
MT, WF, JD, KM, EJvR, TH, HN, JLH, TD, KC, JR-F, ZLT, PR, IC, PP, HT, FAO, JGD
contributed to the inclusion of the PALB2 rare variants on iCOGS. DFE coordinated
the BCAC project and contributed to statistical analysis along with DEG. SVT
contributed to the selection of CHEK2 rare variants. GC-T contributed to the
selection of rare variants in ATM. AD, CL and JD made signiﬁcant contribution to
the data quality related to the calling of the rare genetics variants on iCOGS. MKS,
AB, FBH, SV, JC, CC, RJS, PAF, LH, ABE, MWB, JP, IDSS, OF, NJ, MKB, EJS, IT, MJK,
NM, FM, BB, RY, PG, TT, FM, MS, SB, SFN, HF, JB, MPZ, JIAP, PM, HAC, SN, AZ,
CCD, HB, VA, CS, HB, TB, YDK, TAM, KA, CB, NVB, NNA, AL, SM, AM, VK, V-MK,
JMH, AS, EW, DS, BB, GF, JCC, AR, PS, DFJ, JEO, CV, VSP, CM, CAH, BEH, FS,
LLM, VK, GGA, WZ, DJH, SL, SEH, PK, IA, JAK, GG, AMM, AJV, MG, SK, PD,
RAEMT, CS, AH, MGC, JF, SJC, JL, KC, HD, ME, DME, SR, WJT, SMG, MJH, JWMM,
JMC, MTL, PH, JL, JSB, KH, AC, MWRR, CL, CB, AD, UH, DT, HUU, TR, AJ, JL, KJ,
KD, SS, AET, CBA, DY, AS, AA, NO, MJ, AGN, GP, MRA, NA, DH, DCT, DV, FB, JS,
MD, PS, RE, KM, FW, HG, JS, MW, BGN, RCT, DN, JLD, FCH, KTK, JLS, WJB, ST,
DJS, JLK, CM, ASK, CC, LCA, KB, JP, RK, JB, MRT, ZKJ, AAAO, SB, SPR, AH, AH,
MR, DL, EVN, IV, SL, JAD, MAR, SN, UE, SWG, KO, LES, GF, GL, JLK, LRW, MTG,
IR, PAH, LMP, RB, FM, RPE, RBN, KBM, ADB, FH, PH, SK, BYK, CW, JL, AJ, SKK,
EH, BP, BB, LB, ELG, BLF, RAV, JMC, MCL, ZCF, KRK, DL, KHL, MATH, XW, DAL,
FD, MB, AB, ESI, JRM, LA, DWC, KLT, ELP, MS, SST, EVB, IO, SHO, LB, HBS, AMVA,
KKHA, LAK, LFAGM, TP, YB, ABW, LEK, LSC, NDL, BG, JG, JM, CKH, LL, LN, SAE,
ED, JT, IC, IN, JP, NS, RG, ASW, JHR, VG, WS, HC, XOS, RTT, RS, JRM, SAN, CP,
ANM, DF, HYL, JPW, TAS, TAC, YYT, ZC, AGM, SAG, SJR, UM, AHW, CLP, DVDB,
MCP, ADM, JPH, JMS, JK, PP, HS, IW, GC-T, GGG, SVT, DFE, RLM provided DNA
samples and/or phenotypical data. All authors read and approved the ﬁnal manuscript.
Funding Funding for the iCOGS infrastructure came from: the European
Community’s Seventh Framework Programme under grant agreement n° 223175
(HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A
10710, C12292/A11174, C5047/A8384, C5047/A15007, C5047/A10692, CRUK
C8197/A10123), the National Institutes of Health (CA128978) and Post-Cancer
GWAS initiative (No. 1 U19 CA 148537—the GAME-ON initiative), the Department
of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research
(CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for
the Cure, the Breast Cancer Research Foundation, the Ovarian Cancer Research
Fund and Susan G Komen (WF).
Further information about the ﬁnancial report received is outlined in the
supplementary ﬁle online.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement This would vary for each study—each study is listed in
the supplemental material.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility.
Nat Genet 2008;40:17–22.
2 Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K,
Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D,
Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR. PALB2,
which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Nat Genet 2007;39:165–7.
3 Southey MC, Teo ZL, Winship I. PALB2 and breast cancer: ready for clinical
translation! Appl Clin Genet 2013;6:43–52.
4 Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A,
Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW,
Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA,
Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent
mutation in PALB2 in Finnish cancer families. Nature 2007;446:316–19.
5 Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC,
Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston
DM, Winqvist R, Hopper JL. Penetrance analysis of the PALB2 c.1592delT founder
mutation. Clin Cancer Res 2008;14:4667–71.
6 Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N,
Apicella C, Byrnes GB, Winship I, Baglietto L, Giles GG, Goldgar DE, Foulkes WD,
Southey MC, et al. J Med Genet 2016;53:800–811. doi:10.1136/jmedgenet-2016-103839 809
Cancer genetics
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
Hopper JL, kConFab for the Beast Cancer Family Registry. A PALB2 mutation
associated with high risk of breast cancer. Breast Cancer Res 2010;12:R109.
7 Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM,
Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle
AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P Population-based
estimates of breast cancer risks associated with ATM gene variants c.7271T>G and
c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat
2006;27:1122–8.
8 Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H,
Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah
E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H,
Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D,
Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian
cancer associated with BRCA1 or BRCA2 mutations detected in case Series
unselected for family history: a combined analysis of 22 studies. Am J Hum Genet
2003;72:1117–30.
9 Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A,
Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S,
Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A,
Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE,
Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon
P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N,
Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes
WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl
J Med 2014;371:497–506.
10 Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C,
Nevanlinna H. The breast cancer susceptibility mutation PALB2 1592delT is associated
with an aggressive tumor phenotype. Clin Cancer Res 2009;15:3214–22.
11 Le Calvez-Kelm F, Lesueur F, Damiola F, Vallée M, Voegele C, Babikyan D, Durand
G, Forey N, McKay-Chopin S, Robinot N, Nguyen-Dumont T, Thomas A, Byrnes GB,
Breast Cancer Family Registry, Hopper JL, Southey MC, Andrulis IL, John EM,
Tavtigian SV. Rare, evolutionarily unlikely missense substitutions in CHEK2
contribute to breast cancer susceptibility: results from a breast cancer family registry
case-control mutation-screening study. Breast Cancer Res 2011;13:R6.
12 Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F,
Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe
M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM,
Whiteman DC, Australian Cancer Study; Breast Cancer Family Registries (BCFR);
Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of
Breast Cancer (kConFab), Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John
EM, Chenevix-Trench G. Rare, evolutionarily unlikely missense substitutions in ATM
confer increased risk of breast cancer. Am J Hum Genet 2009;85:427–46.
13 Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly
MJ, Buys SM, Southey MC, Andrulis I, John EM, BCFR; kConFab, Khanna KK,
Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G. Rare variants in the ATM gene
and risk of breast cancer. Breast Cancer Res 2011;13:R73.
14 Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in
BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358–65.
15 Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R,
Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe
A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA,
Easton DF, Eeles RA, Cancer Research UK/Bristish Prostate Group UK Familial
Prostate Cancer Study Collaborators; British Association of Urological Surgeons
Section of Oncology. Two percent of men with early-onset prostate cancer harbor
germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1–12.
16 Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl
Cancer Inst 1999;91:1310–16.
17 Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E,
Goh C, Govindasami K, Guy M, O’Brien L, Sawyer E, Hall A, Wilkinson R, Easton D,
UKGPCS, CollaboratorsGoldgar D, Eeles R, Kote-Jarai Z. Germline BRCA1 mutations
increase prostate cancer risk. Br J Cancer 2012;106:1697–701.
18 Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA.
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary
prostate cancer. Prostate 2008;68:675–8.
19 Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D,
Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J. A novel germline PALB2
deletion in Polish breast and ovarian cancer patients. BMC Med Genet 2010;11:20.
20 Teo ZL, Park DJ, Provenzano E, Chatﬁeld CA, Odefrey FA, Nguyen-Dumont T,
kConFab, Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC. Prevalence of
PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer
Res 2013;15:R17.
21 Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward ﬁndings for
hormonally mediated cancers. Nat Genet 2013;45:345–8.
22 Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt
MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C,
Rahman N, Breast and Ovarian Cancer Susceptibility Collaboration, Fletcher O, Peto
J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist
C, Czene K, Irwanto A, Liu J, Waisﬁsz Q, Meijers-Heijboer H, Adank M, Hereditary
Breast and Ovarian Cancer Research Group Netherlands (HEBON), van der Luijt RB,
Hein R, Dahmen N, Beckman L, Meindl A, Schmutzler RK, Müller-Myhsok B,
Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, Uitterlinden AG,
Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S,
Wessels LF, Haiman CA, Shah M, Luben R, Brown J, Luccarini C, Schoof N,
Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger H, Couch FJ, Wang X,
Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens R, Christiaens MR,
Rudolph A, Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Aaltonen K, Heikkinen
T, Broeks A, Veer LJ, van der Schoot CE, Guénel P, Truong T, Laurent-Puig P,
Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Perez JI,
Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MW, Sawyer EJ, Tomlinson I,
Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL,
Knight JA, Glendon G, Mulligan AM, kConFab Investigators, Australian Ovarian
Cancer Study Group, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, van den
Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles
GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW,
Brenner H, Müller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones
M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labrèche F, Dumont M,
Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Brüning T,
GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network,
Radice P, Peterlongo P, Manoukian S, Bonanni B, Devilee P, Tollenaar RA, Seynaeve
C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A,
Kataja V, Kosma VM, Hartikainen JM, Bogdanova NV, Antonenkova NN, Dörk T,
Kristensen VN, Anton-Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo
KY, Noh DY, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng CC, Van Den Berg
D, Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK,
Hartman M, Miao H, Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S,
Siriwanarangsan P, Shen CY, Hsiung CN, Wu PE, Ding SL, Sangrajrang S, Gaborieau
V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson
S, Shrubsole M, Long J, Simard J, Garcia-Closas M, Pharoah PD, Chenevix-Trench
G, Dunning AM, Benitez J, Easton DF. Large-scale genotyping identiﬁes 41 new loci
associated with breast cancer risk. Nat Genet. 2013;45:353–61.
23 Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M,
Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC,
Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Australian Cancer Study,
Australian Ovarian Cancer Study Group, Aben KK, Anton-Culver H, Antonenkova N,
Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G,
Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R,
Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow
WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C,
Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M,
Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT,
Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q,
Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Høgdall E, Høgdall
CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE,
Kiemeney LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D,
Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubiński J,
Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U,
Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S,
Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM,
Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L,
Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I,
Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K,
Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den
Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N,
Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas
A, Zulkiﬂi F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A,
Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA.
GWAS meta-analysis and replication identiﬁes three new susceptibility loci for
ovarian cancer. Nat Genet 2013;45:362–70.
24 Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K,
Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dörk T, Bendix R, Kirk J,
Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK. Dominant
negative ATM mutations in breast cancer families. J Natl Cancer Inst
2002;94:205–15.
25 Benjamini, Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc Series B 1995;57:289–300.
26 Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M,
Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE,
Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H,
Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P,
Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J,
Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM,
Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello
LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J,
Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements
JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ,
Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley
810 Southey MC, et al. J Med Genet 2016;53:800–811. doi:10.1136/jmedgenet-2016-103839
Cancer genetics
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ,
Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A,
Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M,
Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A,
Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder
MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi
DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G,
Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA,
Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney
KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, COGS–Cancer Research UK
GWAS–ELLIPSE (part of GAME-ON) Initiative, Australian Prostate Cancer
Bioresource, UK Genetic Prostate Cancer Study Collaborators/British Association of
Urological Surgeons’ Section of Oncology, UK ProtecT (Prostate testing for cancer
and Treatment) Study Collaborators, PRACTICAL (Prostate Cancer Association Group
to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai
Z, Easton DF. Identiﬁcation of 23 new prostate cancer susceptibility loci using the
iCOGS custom genotyping array. Nat Genet 2013;45:385–91.
27 Glusman G. Clinical applications of sequencing take center stage. Genome Biol
2013;14:303.
28 Sikkema-Raddatz B, Johansson LF, de Boer EN, Almomani R, Boven LG, van den
Berg MP, van Spaendonck-Zwarts KY, van Tintelen JP, Sijmons RH, Jongbloed JD,
Sinke RJ. Targeted Next-Generation Sequencing can Replace Sanger Sequencing in
Clinical Diagnostics. Hum Mutat 2013;34:1035–42.
29 Rattenberry E, Vialard L, Yeung A, Bair H, McKay K, Jafri M, Canham N, Cole TR,
Denes J, Hodgson SV, Irving R, Izatt L, Korbonits M, Kumar AV, Lalloo F, Morrison PJ,
Woodward ER, Macdonald F, Wallis Y, Maher ER. A comprehensive next generation
sequencing based genetic testing strategy to improve diagnosis of inherited
pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013;98:E1248–56.
30 Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, Meetei AR,
Andreassen PR. Breast cancer-associated missense mutants of the PALB2 WD40
domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Oncogene 2014;33:4803–12.
31 Taylor AM, Lam Z, Last JI, Byrd PJ. Ataxia telangiectasia: more variation at clinical
and cellular levels. Clin Genet 2015;87:199–208. Mar.
32 Waddell N, Jonnalagadda J, Marsh A, Grist S, Jenkins M, Hobson K, Taylor M,
Lindeman GJ, Tavtigian SV, Suthers G, Goldgar D, Oefner PJ, kConFab Investigators,
Taylor D, Grimmond S, Khanna KK, Chenevix-Trench G. Characterization of the
breast cancer associated ATM 7271T<G (V2424G) mutation by gene expression
proﬁling. Genes Chromosomes Cancer 2006;45:1169–81.
33 Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk:
meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol
2008;26:542–8.
34 Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility:
evidence from a meta-analysis. DNA Cell Biol 2013;32:329–35.
35 Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV,
Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG,
Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD. Gene-panel
sequencing and the prediction of breast-cancer risk. N Engl J Med
2015;372:2243–57.
Southey MC, et al. J Med Genet 2016;53:800–811. doi:10.1136/jmedgenet-2016-103839 811
Cancer genetics
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
cancer risk: data from COGS
 rare variants andATM and CHEK2, PALB2
doi: 10.1136/jmedgenet-2016-103839
2016
2016 53: 800-811 originally published online September 5,J Med Genet 
 http://jmg.bmj.com/content/53/12/800
Updated i formation and services can be found at: These include:R ferences
 #BIBL
is article cites 35 articles, 6 of wh ch you can ccess for fr e at: Op n Ac
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Com ons Attribution (CC BY 4.0) license, which permits 
is an Open Access article di tributed in ccor ance with th  terms of
service
Em il al rti g
box at the top right corner of the online article.
Rec ive fre  mail alerts when new ar icles cite this article. Sign up in the
Collections
TopicArticl s on simil r topics can be found in the foll wing co l ctions
 (628)Epidemiology
 (70)Urological cancer
 (24)Prostate cancer
 (239)Breast ancer
 (177)Open access
 (116)Editor's choiceNote
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
Giles, Sean V Tavtigian, Doug F Easton and Roger L Milne
Honglin Song, Ingrid Winship, Georgia Chenevix-Trench, Graham G
Joanna Moes-Sosnowska, Jolanta Kupryjanczyk, Paul DP Pharoah, 
Pike, Agnieszka Dansonka-Mieszkowska, Joanna Plisiecka-Halasa,
Menon, Anna H Wu, Celeste L Pearce, David Van Den Berg, Malcolm C 
Aleksandra Gentry-Maharaj, Simon A Gayther, Susan J Ramus, Usha
Permuth, Thomas A Sellers, Y Ann Chen, Ya-Yu Tsai, Zhihua Chen, 
Phelan, Alvaro N Monteiro, David Fenstermacher, Hui-Yi Lin, Jennifer B
Rebecca Sutphen, John R McLaughlin, Steven A Narod, Catherine M 
Valerie McGuire, Weiva Sieh, Hui Cai, Xiao-Ou Shu, Rachel T Teten,
Siddiqui, Rosalind Glasspool, Alice S Whittemore, Joseph H Rothstein, 
NadeemDicks, Jonathan Tyrer, Ian Campbell, Iain McNeish, James Paul, 
Høgdall, Lene Lundvall, Lotte Nedergaard, Svend Aage Engelholm, Ed
D Le, Bohdan Górski, Jacek Gronwald, Janusz Menkiszak, Claus K 
NhuYukie Bean, Angela Brooks-Wilson, Linda E Kelemen, Linda S Cook, 
K H Aben, Lambertus A Kiemeney, Leon F A G Massuger, Tanja Pejovic,
Sara H Olson, Line Bjorge, Helga B Salvesen, Anne M van Altena, Katja 
Poole, Meir Stampfer, Shelley S Tworoger, Elisa V Bandera, Irene Orlow,
Daniel W Cramer, Joellen Schildkraut, Kathryn L Terry, Elizabeth M 
Andrew Berchuck, Edwin S Iversen, Jeffrey R Marks, Lucy Akushevich,
T Hildebrandt, Xifeng Wu, Douglas A Levine, Fanny Dao, Maria Bisogna, 
Zachary C Fogarty, Kimberly R Kalli, Dong Liang, Karen H Lu, Michelle A
Fridley, Robert A Vierkant, Julie M Cunningham, Melissa C Larson, 
Peissel, Bernardo Bonanni, Loris Bernard, Ellen L Goode, Brooke L
Lester, Allan Jensen, Susanne Krüger Kjaer, Estrid Høgdall, Bernard 
Philipp Harter, Stefan Kommoss, Beth Y Karlan, Christine Walsh, Jenny
Roberta B Ness, Kirsten B Moysich, Andreas du Bois, Florian Heitz, 
M Pelttari, Ralf Butzow, Francesmary Modugno, Robert P Edwards,
Wilkens, Marc T Goodman, Ingo Runnebaum, Peter A Hillemanns, Liisa 
Sucheston-Campbell, Grace Friel, Galina Lurie, Jeffrey L Killeen, Lynne R
Nickels, Ursula Eilber, Shan Wang-Gohrke, Kunle Odunsi, Lara E 
Sandrina Lambretchs, Jennifer A Doherty, Mary Anne Rossing, Stefan
Ruebner, Diether Lambrechts, Els Van Nieuwenhuysen, Ignace Vergote, 
Benlloch, Stefan P Renner, Arndt Hartmann, Alexander Hein, Matthias
Batra, Manuel R Teixeira, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara 
Cannon-Albright, Katja Butterbach, Jong Park, Radka Kaneva, Jyotsna
Joseph L Kelley, Christiane Maier, Adam S Kibel, Cezary Cybulski, Lisa 
Janet L Stanford, William J Blot, Stephen Thibodeau, Daniel J Schaid,
Travis, David Neal, Jenny L Donovan, Freddie C Hamdy, Kay-Tee Khaw, 
Johanna Schleutker, Børge G Nordestgaard, Maren Weischer, Ruth C
Rosalind Eeles, Kenneth Muir, Fredrik Wiklund, Henrik Gronberg, 
Francois Bacot, Jacques Simard, Martine Dumont, Penny Soucy,
Alonso, Nuria Álvarez, Daniel Herrero, Daniel C Tessier, Daniel Vincent, 
Nick Orr, Michael Jones, Anna González-Neira, Guillermo Pita, M Rosario
Ambrosone, Drakoulis Yannoukakos, Anthony Swerdlow, Alan Ashworth, 
Katarzyna Durda, Susan Slager, Amanda E Toland, Christine B
Thomas Rüdiger, Anna Jakubowska, Jan Lubinski, Katarzyna Jaworska, 
Alison M Dunning, Ute Hamann, Diana Torres, Hans Ulrich Ulmer,
Angela Cox, Malcolm W R Reed, Craig Luccarini, Caroline Baynes, 
Tilanus-Linthorst, Per Hall, Jingmei Li, Judith S Brand, Keith Humphreys,
Maartje J Hooning, John W M Martens, J Margriet Collée, Madeleine 
Eriksson, Diana M Eccles, Sajjad Rafiq, William J Tapper, Sue M Gerty,
Chanock, Jolanta Lissowska, Kamila Czene, Hatef Darabi, Mikael 
Hollestelle, Montserrat Garcia-Closas, Jonine Figueroa, Stephen J
Devilee, Robert A E M Tollenaar, Caroline Seynaeve, Antoinette 
Mulligan, Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Peter
Peter Kraft, Irene Andrulis, Julia A Knight, Gord Glendon, Anna Marie 
Alnæs, Wei Zheng, David J Hunter, Sara Lindstrom, Susan E Hankinson,
Schumacher, Loic Le Marchand, Vessela Kristensen, Grethe Grenaker 
Catriona McLean, Christopher A Haiman, Brian E Henderson, Fredrick
Dieter Flesch-Janys, Janet E Olson, Celine Vachon, Vernon S Pankratz, 
Giuseppe Floris, Jenny Chang-Claude, Anja Rudolph, Petra Seibold,
Study Group, Els Wauters, Dominiek Smeets, Benoit Beuselinck, 
Amanda B Spurdle, kConFab Investigators, Australian Ovarian Cancer
Arto Mannermaa, Vesa Kataja, Veli-Matti Kosma, Jaana M Hartikainen, 
Bogdanova, Natalia N Antonenkova, Annika Lindblom, Sara Margolin,
Taru A Muranen, Kristiina Aittomäki, Carl Blomqvist, Natalia V 
Christa Stegmaier, Hiltrud Brauch, Thomas Brüning, Yon-Dschun Ko,
Argyrios Ziogas, Christina A Clarke, Hermann Brenner, Volker Arndt, 
Arias Perez, Primitiva Menéndez, Hoda Anton-Culver, Susan Neuhausen,
Nielsen, Henrik Flyger, Javier Benitez, M Pilar Zamora, Jose Ignacio 
Truong, Florence Menegaux, Marie Sanchez, Stig Bojesen, Sune F
Marme, Barbara Burwinkel, Rongxi Yang, Pascal Guénel, Thérèse 
Elinor J Sawyer, Ian Tomlinson, Michael J Kerin, Nicola Miller, Federik
dos-Santos-Silva, Olivia Fletcher, Nichola Johnson, Manjeet K Bolla, 
Haeberle, Arif B Ekici, Matthias W Beckmann, Julian Peto, Isabel
Carpenter, Christine Clarke, Rodney J Scott, Peter A Fasching, Lothar 
Schmidt, Annegien Broeks, Frans B Hogervorst, Senno Verhoef, Jane
Helen Tsimiklis, Fabrice A Odefrey, James G Dowty, Marjanka K 
Reis-Filho, Zhi Ling Teo, Paolo Radice, Irene Catucci, Paolo Peterlongo,
Nevanlinna, John L Hopper, Thilo Dörk, Kathleen BM Claes, Jorge 
Michailidou, Elizabeth J van Rensburg, Tuomas Heikkinen, Heli
Fergus Couch, Marc Tischkowitz, William D Foulkes, Joe Dennis, Kyriaki 
Melissa C Southey, David E Goldgar, Robert Winqvist, Katri Pylkäs,
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on November 29, 2016 - Published by http://jmg.bmj.com/Downloaded from 
